Skip to main content
Midas Edge

Disc Medicine Inc

For the period ended Sep 30, 2024. Filed Nov 12, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 12, 2024

IRON$84.64+4.2%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Condensed Consolidated Statements of Stockholders’ Equity

Common Stock$0.0001 Par Value · ​ · Additional Paid-In · Accumulated OtherComprehensive · Accumulated · TotalStockholders’
Shares​Amount​CapitalIncome (Loss)DeficitEquity
Balance at December 31, 202324,360,233​$2$533,764$—$(188,645)$345,121
Issuance of common stock upon exercise of stock options95,467​—​806——806
Stock-based compensation expense—​—​4,058——4,058
Sale of common stock in at-the-market offerings, net of issuance costs of $518234,449—14,790——14,790
Issuance of common stock under employee stock purchase plan5,736—245——245
Net loss—​—​——(26,949)(26,949)
Balance at March 31, 202424,695,885​$2$553,663$—$(215,594)$338,071
Issuance of common stock upon exercise of stock options68,112​—​567——567
Stock-based compensation expense—​—​4,091——4,091
Sale of common stock in registered direct offering, net of issuance costs of $5,4724,944,0001172,511——172,512
Foreign currency translation adjustments———6—6
Unrealized loss on marketable securities———(66)—(66)
Net loss—​—​——(26,352)(26,352)
Balance at June 30, 202429,707,997​$3$730,832$(60)$(241,946)$488,829
Issuance of common stock upon exercise of stock options34,811​—​401——401
Stock-based compensation expense—​—​4,332——4,332
Issuance of common stock under employee stock purchase plan5,346—196——196
Foreign currency translation adjustments———(48)—(48)
Unrealized gain on marketable securities———849—849
Net loss—​—​——(26,599)(26,599)
Balance at September 30, 202429,748,154​$3$735,761$741$(268,545)$467,960

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (Continued)

Common Stock$0.0001 Par Value · ​ · Additional Paid-In · Accumulated OtherComprehensive · Accumulated · TotalStockholders’
Shares​Amount​CapitalIncome (Loss)DeficitEquity
Balance at December 31, 202217,403,315​$2​$288,814$—$(112,216)$176,600
Issuance of common stock upon exercise of stock options74,753​—​1,067——1,067
Vesting of restricted common stock958​—​————
Stock-based compensation expense—​—​1,024——1,024
Sale of common stock in registered direct offering, net of issuance costs of $801,488,166​—​34,148——34,148
Sale of pre-funded warrants in registered direct offering, net of issuance costs of $66——28,206——28,206
Sale of common stock in at-the-market offerings, net of issuance costs of $408608,050—14,591——14,591
Net loss—​—​——(22,781)(22,781)
Balance at March 31, 202319,575,242​$2​$367,850$—$(134,997)$232,855
Issuance of common stock upon exercise of stock options41,475​—​242——242
Vesting of restricted common stock958​—​————
Stock-based compensation expense—​—​1,309——1,309
Sale of common stock in follow-on public offering, net of issuance costs of $9,2723,015,919​—​138,508——138,508
Sale of pre-funded warrants in follow-on public offering, net of issuance costs of $627——9,373——9,373
Sale of common stock in at-the-market offerings, net of issuance costs of $119217,300—4,879——4,879
Net loss—​—​——(15,947)(15,947)
Balance at June 30, 202322,850,894​$2​$522,161$—$(150,944)$371,219
Issuance of common stock upon exercise of stock options58,963​—​607——607
Stock-based compensation expense—​—​1,270——1,270
Issuance of common stock upon exercise of warrants1,229,221​—​————
Net loss—​—​——(14,122)(14,122)
Balance at September 30, 202324,139,078​$2​$524,038$—$(165,066)$358,974
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.